A digital view of the world illustrates how Astellas is a global company committed to serving patients worldwide.

News

Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.

Month Year

Jul 10, 2018

Seattle Genetics and Astellas Announce Progress in Enfortumab Vedotin Urothelial Cancer Clinical Development Program

-Enrollment of EV-201 Pivotal Trial Cohort Designed to Support Potential Expedited Registration Pathway in the U.S. Completed-

BOTHELL, Wash., and TOKYO, July 9, 2018 – Seattle Genetics, Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced...

Read more about Seattle Genetics and Astellas Announce Progress in Enfortumab Vedotin Urothelial Cancer Clinical Development Program
Jul 2, 2018

Astellas Announces Status of Acquisition of Own Shares

Read more about Astellas Announces Status of Acquisition of Own Shares
Jul 2, 2018

Astellas Received Approval for Dafclir® Tablets for the Treatment of Infectious Enteritis Caused by Clostridium difficile in Japan

TOKYO, July 2, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) today announced that it has received an approval for the marketing application of...

Read more about Astellas Received Approval for Dafclir® Tablets for the Treatment of Infectious Enteritis Caused by Clostridium difficile in Japan
Jun 29, 2018

Results from Pivotal Phase 3 PROSPER Trial of XTANDI® (enzalutamide) in Men with Non-Metastatic Castration-Resistant Prostate Cancer Published in New England Journal of Medicine

Results show enzalutamide plus androgen deprivation therapy significantly reduced the risk of developing metastases or death by 71 percent compared to placebo plus androgen deprivation therapy

TOKYO, June 29, 2018 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that results from the pivotal Phase 3 PROSPER trial, which...

Read more about Results from Pivotal Phase 3 PROSPER Trial of XTANDI® (enzalutamide) in Men with Non-Metastatic Castration-Resistant Prostate Cancer Published in New England Journal of Medicine
Jun 28, 2018

Astellas Named to FTSE4Good Index Series for the Seventh Consecutive Year

Tokyo, June 28, 2018 - Astellas Pharma Inc. (President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that it has been selected for the seventh consecutive year to be included in...

Read more about Astellas Named to FTSE4Good Index Series for the Seventh Consecutive Year
Jun 26, 2018

Astellas Announces Personnel Change

Astellas Announces Personnel Change

Read more about Astellas Announces Personnel Change
Jun 11, 2018

Astellas Announces Launch of XTANDI® Tablets in Japan for the Treatment of Castration-Resistant Prostate Cancer

TOKYO, June 11, 2018 - Astellas Pharma Inc. (President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) today announced that it launched 40 mg XTANDI® (generic name enzalutamide) Tablets and 80...

Read more about Astellas Announces Launch of XTANDI® Tablets in Japan for the Treatment of Castration-Resistant Prostate Cancer
Jun 4, 2018

Astellas and Seattle Genetics Present at ASCO 2018 on Enfortumab Vedotin in Patients with Locally Advanced or Metastatic Urothelial Cancer Previously Treated with Checkpoint Inhibitor Therapy

-Updated Data from Phase 1 EV-101 Study Highlighted in ASCO 2018 Oral Presentation Support Rapid Development Program and Ongoing Pivotal Study-

TOKYO and BOTHELL, Wash. – June 3, 2018 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Seattle Genetics, Inc. (Nasdaq: SGEN) today announced...

Read more about Astellas and Seattle Genetics Present at ASCO 2018 on Enfortumab Vedotin in Patients with Locally Advanced or Metastatic Urothelial Cancer Previously Treated with Checkpoint Inhibitor Therapy
Jun 1, 2018

Astellas Announces Personnel Change

Astellas Announces Personnel Change

Read more about Astellas Announces Personnel Change
May 31, 2018

Astellas Announces Acquisition of Own Shares

Tokyo, May 31, 2018- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D.) today announced that at the meeting of the Board of Directors held today, a resolution was adopted...

Read more about Astellas Announces Acquisition of Own Shares

Show per page

Discover more

Media contacts

Return to media homepage

Subscribe to news alerts

Su	Mo	Tu	We	Th	Fr	Sa

Su	Mo	Tu	We	Th	Fr	Sa

Choose Language

News